

Reginald F Frye

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3277076/publications.pdf>

Version: 2024-02-01

142
papers

5,726
citations

66234

42
h-index

95083

68
g-index

143
all docs

143
docs citations

143
times ranked

6021
citing authors

#	ARTICLE	IF	CITATIONS
1	DHEA and DHEA-S: A Review. <i>Journal of Clinical Pharmacology</i> , 1999, 39, 327-348.	1.0	451
2	Validation of the five-drug "Pittsburgh cocktail" approach for assessment of selective regulation of drug-metabolizing enzymes*. <i>Clinical Pharmacology and Therapeutics</i> , 1997, 62, 365-376.	2.3	219
3	Effect of St John's wort on imatinib mesylate pharmacokinetics. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 76, 323-329.	2.3	204
4	Liver disease selectively modulates cytochrome P450-mediated metabolism. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 80, 235-245.	2.3	203
5	INDUCTION AND INHIBITION OF CYTOCHROMES P450 BY THE ST. JOHN'S WORT CONSTITUENT HYPERFORIN IN HUMAN HEPATOCYTE CULTURES. <i>Drug Metabolism and Disposition</i> , 2004, 32, 512-518.	1.7	168
6	Plasma levels of TNF- α and IL-6 are inversely related to cytochrome P450-dependent drug metabolism in patients with congestive heart failure. <i>Journal of Cardiac Failure</i> , 2002, 8, 315-319.	0.7	144
7	Cytochrome P450 mediated-drug metabolism is reduced in children with sepsis-induced multiple organ failure. <i>Intensive Care Medicine</i> , 2003, 29, 980-984.	3.9	135
8	Bioequivalence revisited: Influence of age and sex on CYP enzymes. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 76, 618-627.	2.3	129
9	Effects of high-fructose corn syrup and sucrose on the pharmacokinetics of fructose and acute metabolic and hemodynamic responses in healthy subjects. <i>Metabolism: Clinical and Experimental</i> , 2012, 61, 641-651.	1.5	127
10	ESRD Impairs Nonrenal Clearance of Fexofenadine but not Midazolam. <i>Journal of the American Society of Nephrology: JASN</i> , 2009, 20, 2269-2276.	3.0	111
11	Hepatic drug metabolism and transport in patients with kidney disease. <i>American Journal of Kidney Diseases</i> , 2003, 42, 906-925.	2.1	103
12	Determinants of vancomycin clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis. <i>American Journal of Kidney Diseases</i> , 1998, 31, 1019-1027.	2.1	97
13	Tolbutamide, Flurbiprofen, and Losartan as Probes of CYP2C9 Activity in Humans. <i>Journal of Clinical Pharmacology</i> , 2003, 43, 84-91.	1.0	86
14	In vivo modulation of CYP enzymes by quinidine and rifampin. <i>Clinical Pharmacology and Therapeutics</i> , 2000, 68, 401-411.	2.3	85
15	Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping. <i>Clinical Pharmacology and Therapeutics</i> , 2002, 72, 718-728.	2.3	83
16	Effects of Herbal Supplements on Drug Glucuronidation. Review of Clinical, Animal, and <i>In Vitro</i> Studies. <i>Planta Medica</i> , 2011, 77, 311-321.	0.7	79
17	Drug Administration in Patients with Renal Insufficiency Minimising Renal and Extrarenal Toxicity. <i>Drug Safety</i> , 1997, 16, 205-231.	1.4	77
18	Pharmacokinetics of mangostin in rats after intravenous and oral application. <i>Molecular Nutrition and Food Research</i> , 2011, 55, S67-74.	1.5	73

#	ARTICLE	IF	CITATIONS
19	Pharmacometabolomics Reveals Racial Differences in Response to Atenolol Treatment. <i>PLoS ONE</i> , 2013, 8, e57639.	1.1	68
20	A sensitive and specific liquid chromatography-tandem mass spectrometry method for the determination of intracellular and extracellular uric acid. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2009, 877, 2032-2038.	1.2	64
21	Chloroquine modulation of specific metabolizing enzymes activities: investigation with selective five drug cocktail. <i>British Journal of Clinical Pharmacology</i> , 1998, 46, 215-219.	1.1	60
22	Evaluation of the Influence of Diabetes Mellitus on Antipyrine Metabolism and CYP1A2 and CYP2D6 Activity. <i>Pharmacotherapy</i> , 2000, 20, 182-190.	1.2	58
23	Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites. <i>Clinical Pharmacology and Therapeutics</i> , 2003, 73, 178-191.	2.3	58
24	Differences in flurbiprofen pharmacokinetics between CYP2C9*1/*1, *1/*2, and *1/*3 genotypes. <i>European Journal of Clinical Pharmacology</i> , 2003, 58, 791-794.	0.8	58
25	Pharmacogenomics competencies in pharmacy practice: A blueprint for change. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2017, 57, 120-125.	0.7	58
26	Determination of chlorzoxazone and 6-hydroxychlorzoxazone in human plasma and urine by high-performance liquid chromatography. <i>Biomedical Applications</i> , 1996, 686, 291-296.	1.7	57
27	Pharmacokinetics of Intermittent Intraperitoneal Cefazolin in Continuous Ambulatory Peritoneal Dialysis Patients. <i>Peritoneal Dialysis International</i> , 1999, 19, 65-70.	1.1	56
28	Simultaneous determination of uric acid metabolites allantoin, 6-aminouracil, and triuret in human urine using liquid chromatography-mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2009, 877, 65-70.	1.2	54
29	The effect of trimethoprim on CYP2C8 mediated rosiglitazone metabolism in human liver microsomes and healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2005, 59, 70-79.	1.1	53
30	Cefazolin as empiric therapy in hemodialysis-related infections: Efficacy and blood concentrations. <i>American Journal of Kidney Diseases</i> , 1998, 32, 410-414.	2.1	52
31	Pharmacokinetics of Intermittent Intravenous Cefazolin and Tobramycin in Patients Treated with Automated Peritoneal Dialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2000, 11, 1310-1316.	3.0	51
32	Pioglitazone improves hepatic mitochondrial function in a mouse model of nonalcoholic steatohepatitis. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2018, 315, E163-E173.	1.8	50
33	Inhibitory Effects of Commonly Used Herbal Extracts on UDP-Glucuronosyltransferase 1A4, 1A6, and 1A9 Enzyme Activities. <i>Drug Metabolism and Disposition</i> , 2011, 39, 1522-1528.	1.7	48
34	Cyclophosphamide and 4-hydroxycyclophosphamide pharmacokinetics in patients with glomerulonephritis secondary to lupus and small vessel vasculitis. <i>British Journal of Clinical Pharmacology</i> , 2012, 74, 445-455.	1.1	48
35	Minimal in vivo activation of CYP2C9-mediated flurbiprofen metabolism by dapsone. <i>European Journal of Pharmaceutical Sciences</i> , 2001, 14, 47-52.	1.9	47
36	Intravenous Vancomycin Pharmacokinetics in Automated Peritoneal Dialysis Patients. <i>Peritoneal Dialysis International</i> , 2001, 21, 378-385.	1.1	46

#	ARTICLE	IF	CITATIONS
37	The Effects of Milk Thistle (<i>Silybum marianum</i>) on Human Cytochrome P450 Activity. <i>Drug Metabolism and Disposition</i> , 2014, 42, 1611-1616.	1.7	46
38	Inhibitory effects of commonly used herbal extracts on UGT1A1 enzyme activity. <i>Xenobiotica</i> , 2010, 40, 663-669.	0.5	45
39	Effect of chronic disulfiram administration on the activities of CYP1A2, CYP2C19, CYP2D6, CYP2E1, and N-acetyltransferase in healthy human subjects. <i>British Journal of Clinical Pharmacology</i> , 2002, 53, 155-162.	1.1	44
40	Validation of incorporating flurbiprofen into the Pittsburgh cocktail. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 80, 257-263.	2.3	44
41	Early Atorvastatin Reduces Hemorrhage after Acute Cerebral Ischemia in Diabetic Rats. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2009, 330, 532-540.	1.3	44
42	THE EFFECT OF ISONIAZID ON CYP2E1- AND CYP4A-MEDIATED HYDROXYLATION OF ARACHIDONIC ACID IN THE RAT LIVER AND KIDNEY. <i>Drug Metabolism and Disposition</i> , 2004, 32, 727-733.	1.7	43
43	Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 1111-1118.	1.1	43
44	Pharmacokinetics of intermittent intraperitoneal ceftazidime. <i>American Journal of Kidney Diseases</i> , 1999, 33, 111-117.	2.1	42
45	Determinants of Ceftriaxone Clearance by Continuous Venovenous Hemofiltration and Hemodialysis. <i>Pharmacotherapy</i> , 2000, 20, 635-643.	1.2	41
46	Determinants of Ceftazidime Clearance by Continuous Venovenous Hemofiltration and Continuous Venovenous Hemodialysis. <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 1639-1644.	1.4	41
47	High-performance liquid chromatographic assay for acetaminophen glucuronide in human liver microsomes. <i>Biomedical Applications</i> , 2001, 753, 303-308.	1.7	39
48	Sensitive liquid chromatographic method using fluorescence detection for the determination of estradiol 3- and 17-glucuronides in rat and human liver microsomal incubations: formation kinetics. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2002, 774, 33-38.	1.2	39
49	Inhibition of Intestinal and Hepatic Glucuronidation of Mycophenolic Acid by Ginkgo biloba Extract and Flavonoids. <i>Drug Metabolism and Disposition</i> , 2010, 38, 270-275.	1.7	39
50	Determination of famotidine in human plasma and urine by high-performance liquid chromatography. <i>Biomedical Applications</i> , 1999, 732, 239-243.	1.7	37
51	Simplified method for determination of rosiglitazone in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2004, 803, 317-320.	1.2	37
52	Cytochrome P-450 activity is differentially altered in severely injured patients. <i>Critical Care Medicine</i> , 2005, 33, 541-546.	0.4	36
53	Sensitive and specific high-performance liquid chromatographic assay for 4-hydroxyflurbiprofen and flurbiprofen in human urine and plasma. <i>Biomedical Applications</i> , 2000, 749, 119-125.	1.7	35
54	Enzyme- and transporter-mediated beverage-drug interactions: An update on fruit juices and green tea. <i>Journal of Clinical Pharmacology</i> , 2015, 55, 1313-1331.	1.0	35

#	ARTICLE	IF	CITATIONS
55	Use of Chlorzoxazone as an In Vivo Probe of Cytochrome P450 2E1: Choice of Dose and Phenotypic Trait Measure. <i>Journal of Clinical Pharmacology</i> , 1998, 38, 82-89.	1.0	34
56	Influence of DHEA Administration on 24-Hour Cortisol Concentrations. <i>Journal of Clinical Psychopharmacology</i> , 2003, 23, 96-99.	0.7	34
57	Pharmacokinetic Properties of Pure Xanthenes in Comparison to a Mangosteen Fruit Extract in Rats. <i>Planta Medica</i> , 2013, 79, 646-653.	0.7	34
58	Pharmacometabolomic Assessments of Atenolol and Hydrochlorothiazide Treatment Reveal Novel Drug Response Phenotypes. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2015, 4, 669-679.	1.3	34
59	Probing the world of cytochrome P450 enzymes. <i>Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics</i> , 2004, 4, 157-62.	3.4	34
60	Effect of Ceftazidime on Systemic Cytokine Concentrations in Rats. <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 3217-3219.	1.4	33
61	Cefazolin dialytic clearance by high-efficiency and high-flux hemodialyzers. <i>American Journal of Kidney Diseases</i> , 2001, 37, 766-776.	2.1	31
62	A Summer Research Training Program to Foster PharmD Students' Interest in Research. <i>American Journal of Pharmaceutical Education</i> , 2008, 72, 23.	0.7	31
63	Debilitating Reaction following the Initial Dose of Tramadol. <i>Annals of Pharmacotherapy</i> , 1997, 31, 1150-1152.	0.9	29
64	Pyrosequencing Method for Genotyping Cytochrome P450 CYP2C8 and CYP2C9 Enzymes. <i>Clinical Chemistry</i> , 2004, 50, 2392-2395.	1.5	29
65	Cytochrome P450 mRNA expression in peripheral blood lymphocytes as a predictor of enzyme induction. <i>European Journal of Clinical Pharmacology</i> , 2005, 61, 583-593.	0.8	29
66	Current clinical evidence on pioglitazone pharmacogenomics. <i>Frontiers in Pharmacology</i> , 2013, 4, 147.	1.6	29
67	Effect of Cytochrome P450 3A5 Genotype on Atorvastatin Pharmacokinetics and Its Interaction with Clarithromycin. <i>Pharmacotherapy</i> , 2011, 31, 942-950.	1.2	28
68	Concentration-dependent response to pioglitazone in nonalcoholic steatohepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 56-61.	1.9	28
69	Evaluation of gentamicin pharmacokinetics and dosing protocols in 195 neonates. <i>American Journal of Health-System Pharmacy</i> , 1998, 55, 2280-2288.	0.5	27
70	Vancomycin Disposition following Intraperitoneal Administration in Children Receiving Peritoneal Dialysis. <i>Peritoneal Dialysis International</i> , 2007, 27, 79-85.	1.1	26
71	In Vivo Alterations in Drug Metabolism and Transport Pathways in Patients with Chronic Kidney Diseases. <i>Pharmacotherapy</i> , 2014, 34, 114-122.	1.2	26
72	Association of Branched and Aromatic Amino Acids Levels with Metabolic Syndrome and Impaired Fasting Glucose in Hypertensive Patients. <i>Metabolic Syndrome and Related Disorders</i> , 2015, 13, 195-202.	0.5	26

#	ARTICLE	IF	CITATIONS
73	Simplified method for determination of clarithromycin in human plasma using protein precipitation in a 96-well format and liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2008, 871, 130-134.	1.2	25
74	Simultaneous determination of p-aminohippuric acid, acetyl-p-aminohippuric acid and iothalamate in human plasma and urine by high-performance liquid chromatography. <i>Biomedical Applications</i> , 1998, 716, 305-313.	1.7	24
75	Evaluation of flurbiprofen urinary ratios as in vivo indices for CYP2C9 activity. <i>British Journal of Clinical Pharmacology</i> , 2007, 63, 477-487.	1.1	23
76	A Genetic Score Associates With Pioglitazone Response in Patients With Non-alcoholic Steatohepatitis. <i>Frontiers in Pharmacology</i> , 2018, 9, 752.	1.6	23
77	Induction of CYP2E1 activity in liver transplant patients as measured by chlorzoxazone 6-hydroxylation*. <i>Clinical Pharmacology and Therapeutics</i> , 1998, 63, 296-302.	2.3	22
78	Intermittent Intravenous Piperacillin Pharmacokinetics in Automated Peritoneal Dialysis Patients. <i>Peritoneal Dialysis International</i> , 2000, 20, 686-693.	1.1	22
79	Pharmacokinetics of Intraperitoneal Cefepime in Automated Peritoneal Dialysis. <i>Peritoneal Dialysis International</i> , 2005, 25, 380-386.	1.1	22
80	Is a Diabetes Mellitus-Linked Amino Acid Signature Associated With β -Blocker-Induced Impaired Fasting Glucose?. <i>Circulation: Cardiovascular Genetics</i> , 2014, 7, 199-205.	5.1	21
81	A Genetic Response Score for Hydrochlorothiazide Use. <i>Hypertension</i> , 2016, 68, 621-629.	1.3	21
82	Pharmacokinetics and Tissue Distribution of Dodeca-2,4,8,10-tetraenoic Acid Isobutylamides after Oral Administration in Rats. <i>Planta Medica</i> , 2009, 75, 1306-1313.	0.7	20
83	Characterization of tubular functional capacity in humans using para-aminohippurate and famotidine. <i>Kidney International</i> , 2001, 59, 295-303.	2.6	19
84	Effect of Age and Postoperative Time on Cytochrome P450 Enzyme Activity Following Liver Transplantation. <i>Journal of Clinical Pharmacology</i> , 2005, 45, 666-673.	1.0	19
85	Effect of Conjugated Equine Estrogens on Oxidative Metabolism in Middle-aged and Elderly Postmenopausal Women. <i>Journal of Clinical Pharmacology</i> , 2006, 46, 1299-1307.	1.0	19
86	Sphingolipid Metabolic Pathway Impacts Thiazide Diuretics Blood Pressure Response: Insights From Genomics, Metabolomics, and Lipidomics. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	19
87	Improved high-performance liquid chromatographic determination of debrisoquine and 4-hydroxydebrisoquine in human urine following direct injection. <i>Biomedical Applications</i> , 1996, 677, 178-182.	1.7	18
88	Effects of liver disease on the disposition of the opioid antagonist nalmeferne*. <i>Clinical Pharmacology and Therapeutics</i> , 1997, 61, 15-23.	2.3	18
89	Effect of Nortriptyline and Paroxetine on CYP2D6 Activity in Depressed Elderly Patients. <i>Journal of Clinical Psychopharmacology</i> , 2002, 22, 481-486.	0.7	18
90	Coordinated intrahepatic and extrahepatic regulation of cytochrome P4502D6 in healthy subjects and in patients after liver transplantation. <i>Clinical Pharmacology and Therapeutics</i> , 2003, 73, 456-467.	2.3	18

#	ARTICLE	IF	CITATIONS
91	Effect of valerian, valerian/hops extracts, and valerenic acid on glucuronidation in vitro. <i>Xenobiotica</i> , 2007, 37, 113-123.	0.5	18
92	Plasma coenzyme Q10 predicts lipid-lowering response to high-dose atorvastatin. <i>Journal of Clinical Lipidology</i> , 2008, 2, 289-297.	0.6	17
93	Sensitive high-performance liquid chromatographic determination of chlorzoxazone and 6-hydroxychlorzoxazone in plasma. <i>Biomedical Applications</i> , 1993, 613, 127-131.	1.7	16
94	A Sensitive Method for the Simultaneous Determination of Caffeine and its Dimethylxanthine Metabolites in Human Plasma: Application to CYP1A2 Phenotyping. <i>Journal of Liquid Chromatography and Related Technologies</i> , 1998, 21, 1161-1171.	0.5	16
95	Comparison of Iothalamate Clearance Methods for Measuring GFR. <i>Pharmacotherapy</i> , 1999, 19, 943-950.	1.2	16
96	Early thrombin formation capacity in trauma patients and association with venous thromboembolism. <i>Thrombosis Research</i> , 2016, 147, 13-15.	0.8	16
97	The Effect of Renal Insufficiency and Hemodialysis on the Pharmacokinetics of Nalmefene. <i>Journal of Clinical Pharmacology</i> , 1996, 36, 144-151.	1.0	15
98	Determination of 20-hydroxyeicosatetraenoic acid in microsomal incubates using high-performance liquid chromatography-mass spectrometry (HPLC-MS). <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2003, 794, 363-372.	1.2	15
99	Use of Enantiomeric Bupropion and Hydroxybupropion to Assess CYP2B6 Activity in Glomerular Kidney Diseases. <i>Journal of Clinical Pharmacology</i> , 2010, 50, 714-720.	1.0	15
100	Pharmacokinetics of Valerenic Acid in Rats after Intravenous and Oral Administrations. <i>Planta Medica</i> , 2012, 78, 575-581.	0.7	15
101	The effect of milk thistle (<i>Silybum marianum</i>) and its main flavonolignans on CYP2C8 enzyme activity in human liver microsomes. <i>Chemico-Biological Interactions</i> , 2017, 271, 24-29.	1.7	15
102	Sex Differences in the Pharmacokinetics of Dehydroepiandrosterone (DHEA) after Single and Multiple Dose Administration in Healthy Older Adults. <i>Journal of Clinical Pharmacology</i> , 2000, 40, 596-605.	1.0	14
103	Determination of N-desethylamodiaquine by hydrophilic interaction liquid chromatography with tandem mass spectrometry: Application to in vitro drug metabolism studies. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2008, 863, 129-134.	1.2	14
104	Interpopulation Variation Frequency of Human Inosine 5'-Monophosphate Dehydrogenase Type II (<i>IMP2</i>) Genetic Polymorphisms. <i>Genetic Testing and Molecular Biomarkers</i> , 2008, 12, 513-516.	1.7	14
105	Presence of arachidonoyl-carnitine is associated with adverse cardiometabolic responses in hypertensive patients treated with atenolol. <i>Metabolomics</i> , 2016, 12, 1.	1.4	14
106	Inhibitory effect of six herbal extracts on CYP2C8 enzyme activity in human liver microsomes. <i>Xenobiotica</i> , 2015, 45, 406-412.	0.5	13
107	Examination of Metoprolol Pharmacokinetics and Pharmacodynamics Across CYP2D6 Genotype-Derived Activity Scores. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2020, 9, 678-685.	1.3	13
108	The effect of age on the pharmacokinetics of the opioid antagonist nalmefene. <i>British Journal of Clinical Pharmacology</i> , 1996, 42, 301-306.	1.1	12

#	ARTICLE	IF	CITATIONS
109	Stability of Cefepime in Icodextrin Peritoneal Dialysis Solution. <i>Annals of Pharmacotherapy</i> , 2004, 38, 2041-2044.	0.9	12
110	A validated liquid chromatography tandem mass spectrometry method for simultaneous determination of pioglitazone, hydroxypioglitazone, and ketopioglitazone in human plasma and its application to a clinical study. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2014, 969, 219-223.	1.2	12
111	Relative Bioavailability of Silybin A and Silybin B From 2 Multiconstituent Dietary Supplement Formulations Containing Milk Thistle Extract: A Single-dose Study. <i>Clinical Therapeutics</i> , 2018, 40, 103-113.e1.	1.1	12
112	Stereoselective determination of the CYP2C19 probe drug mephenytoin in human urine by gas chromatography-mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2003, 783, 265-271.	1.2	11
113	Validation and application of a liquid chromatography-tandem mass spectrometric method for quantification of the drug transport probe fexofenadine in human plasma using 96-well filter plates. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2010, 878, 497-501.	1.2	11
114	The Role of Pharmacogenetics in the Treatment of Chronic Hepatitis C Infection. <i>Pharmacotherapy</i> , 2014, 34, 185-201.	1.2	11
115	Pharmacokinetics of Intraperitoneal Cefazolin and Ceftazidime Coadministered to CAPD Patients. <i>International Journal of Artificial Organs</i> , 2005, 28, 808-816.	0.7	10
116	Determination of mycophenolic acid glucuronide in microsomal incubations using high performance liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2008, 870, 251-254.	1.2	10
117	Novel plasma biomarker of atenolol-induced hyperglycemia identified through a metabolomics-genomics integrative approach. <i>Metabolomics</i> , 2016, 12, 1.	1.4	10
118	Metabolomic association between venous thromboembolism in critically ill trauma patients and kynurenine pathway of tryptophan metabolism. <i>Thrombosis Research</i> , 2018, 165, 6-13.	0.8	10
119	Effect of pterostilbene on in vitro drug metabolizing enzyme activity. <i>Saudi Pharmaceutical Journal</i> , 2019, 27, 406-412.	1.2	10
120	Nalmefene to Prevent Epidural Narcotic Side Effects in Pediatric Patients: A Pharmacokinetic and Safety Study. <i>Pharmacotherapy</i> , 2000, 20, 745-749.	1.2	9
121	Impaired 6-hydroxychlorzoxazone elimination in patients with kidney disease: implication for cytochrome P450 2E1 pharmacogenetic studies. <i>Clinical Pharmacology and Therapeutics</i> , 2003, 74, 555-568.	2.3	9
122	Determination of trimethoprim in low-volume human plasma by liquid chromatography. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2004, 807, 301-305.	1.2	9
123	Atenolol Exposure and Risk for Development of Adverse Metabolic Effects: A Pilot Study. <i>Pharmacotherapy</i> , 2010, 30, 872-878.	1.2	9
124	Estimation of the Hepatic Extraction Ratio of Indocyanine Green in Swine. <i>Clinical Science</i> , 1993, 84, 681-685.	1.8	8
125	Toxicological and Pharmacokinetic Evaluation of Concomitant Intake of Grapefruit Juice and Simvastatin in Rats after Repeated Treatment over 28 Days. <i>Planta Medica</i> , 2009, 75, 1196-1202.	0.7	8
126	Absolute/Relative Bioavailability and Metabolism of Dodeca-2<i>E</i>,4<i>E</i>,8<i>Z</i>,10<i>E</i>-Tetraenoic Acid Isobutylamides (Tetraenes) after Intravenous and Oral Single Doses to Rats. <i>Planta Medica</i> , 2011, 77, 1794-1799.	0.7	8

#	ARTICLE	IF	CITATIONS
127	Effect of renal insufficiency on CYP activity.. <i>Clinical Pharmacology and Therapeutics</i> , 1996, 59, 155-155.	2.3	7
128	Rapid microtiter plate assay for determination of inulin in human plasma and dialysate. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2002, 28, 209-215.	1.4	7
129	Stability of Atropine Sulfate Prepared for Mass Chemical Terrorism. <i>Journal of Toxicology: Clinical Toxicology</i> , 2003, 41, 771-775.	1.5	7
130	Intensive Care Unit Delirium in Surgical Patients Is Associated with Upregulation in Tryptophan Metabolism. <i>Pharmacotherapy</i> , 2020, 40, 500-506.	1.2	7
131	Pharmacokinetics of abecarnil in patients with renal insufficiency*. <i>Clinical Pharmacology and Therapeutics</i> , 1996, 59, 520-528.	2.3	6
132	Identification of omega hydroxy fatty acids in biological samples as their pentafluoropropyl derivatives by gas chromatography/mass spectrometry with positive and negative ion detection. <i>Rapid Communications in Mass Spectrometry</i> , 2002, 16, 1411-1415.	0.7	6
133	Effect of the Acute Phase Response Induced by Endotoxin Administration on the Expression and Activity of UGT Isoforms in Rats. <i>Drug Metabolism Letters</i> , 2008, 2, 248-255.	0.5	6
134	Determination of visnagin in rat plasma by liquid chromatography with tandem mass spectrometry and its application to in vivo pharmacokinetic studies. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2009, 877, 653-656.	1.2	6
135	Nicotine as a Factor in Stress Responsiveness Among Detoxified Alcoholics. <i>Alcohol and Alcoholism</i> , 2011, 46, 39-51.	0.9	6
136	A Preliminary Study on the Effects of Self-Reported Dietary Caffeine on Pain Experience and Postoperative Analgesia. <i>Journal of Caffeine Research</i> , 2012, 2, 159-166.	1.0	5
137	Effect of disulfiram-mediated CYP2E1 inhibition on the disposition of vesnarinone. <i>Journal of Clinical Pharmacology</i> , 1999, 39, 1177-83.	1.0	5
138	Effect of Low-Furanocoumarin Hybrid Grapefruit Juice Consumption on Midazolam Pharmacokinetics. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 305-311.	1.0	4
139	Impaired 6-hydroxychlorzoxazone elimination in patients with renal insufficiency: Implication for pharmacogenetic studies.. <i>Clinical Pharmacology and Therapeutics</i> , 1996, 59, 168-168.	2.3	1
140	Evaluating an interactive teaching approach with personal genotyping to provide pharmacy students with a knowledge base for clinical pharmacogenetics. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2021, 4, 343-351.	0.5	1
141	A Randomized, Cross-over Trial of Metoprolol Succinate Formulations to Evaluate PK and PD Endpoints for Therapeutic Equivalence. <i>Clinical and Translational Science</i> , 2022, , .	1.5	1
142	1179. <i>Critical Care Medicine</i> , 2015, 43, 296.	0.4	0